The global粘液化市场is estimated to reach USD 6.9 billion by 2026 growing at a CAGR of 8.9% during the forecast period, according to a new study published by Polaris Market Research. The report'粘液市场份额，规模，趋势和行业分析通过产品类型报告（单注射，三次注射，五次注射）;通过施用（膝关节骨关节炎，髋关节骨关节炎，手骨关节炎）;按地区，分部预测，2020 - 2026'provides an extensive analysis of present market dynamics and predicted future trends.
由于全球老年大鼠人口生长，由于患有骨骼关节炎，伤害，牙龈炎和脓肿的发生，这一市场预计将获得牵引力。根据世卫组织的评估，全球65岁及以上人口的人口将从2000年的7％显着增加，估计到2050年的增长率为16％。老年人口的这一显着增长会导致肥胖症和骨浮性关节炎的问题增加，这将间接帮助这个市场在预测期内获得牵引力。随着在全球侵入性外科手术的扩展选择，预计全球范围内的目标群体的上升将大大推动整个预测持续时间内的粘液化需求。
Geographically, North America is estimated to be the largest viscosupplementation market in 2019. According to Centers for Condition Control as well as Avoidance (CDC) in 2015, over 30 million individuals in the United States experienced osteo arthritis and also around 10% individuals over 55 years endured knee discomfort. These growing numbers are pushing the market growth in this region. Asia Pacific on the other hand is anticipated to be the fastest growing market in 2017 and is estimated to preserve its placement throughout the projection period. This growth rate can be made up by the visibility of a considerable growing base of senior citizens, which is vulnerable to problems such as osteo arthritis as well as rheumatoid joint inflammation. Increasing demand for minimally intrusive treatments is a considerable element adding to the growth rate of Asia Pacific. The Latin American market is anticipated to expand at a rewarding pace in the coming years because of the visibility of high unmet clinical requirements, increasing disposable income and growing awareness among the patients in economies such Brazil and Mexico.
有问题吗？在通过单击下面的链接，请在购买此报告之前请求示例或进行查询：//m.ptlymt.com/industry-analysis/viscosupplement-market
Among the viscosupplementation products, three injection products are estimated to be the largest segment of the viscosupplementation market. Affordability and shorter therapy duration are some the major factors which are pushing the growth of this product segment. This is closely followed by the single injection.
米ajor companies operating in the market are focusing on incorporating modern technologies to make innovative viscosupplements. For instance, Anika Therapeutics introduced HYAFF, which aids in production of very efficient biocompatible viscosupplements. The FDA authorized hyaluronates presently offered in the viscosupplementation market are Hyalgan (Sanofi), Euflexxa (Ferring Pharmaceuticals, Inc.), Orthovisc (Anika Rehabs), Supartz, Gel-One (Seikagaku Company), Synvisc, Synvisc One (Genzyme) and also Durolane (Q MEDICATION ABDOMINAL). Some of the major players in this market include Seikagaku Corporation, Lifecore Biomedical, LLC, Zimmer Holdings Inc, Bioventus, Ferring B.V., Sanofi, Anika Therapeutics, Inc., and LG Life Sciences Ltd.
乐动体育软件最新版POLARIS市场研究已根据产品类型，申请和区域进行全球粘液扑塑业市场报告：
产品类型的粘液化展望（收入，百万，2015 - 2026）
- 单注射
- Three Injection
- Five Injection
Viscosupplementation by Application展望（收入，百万，2015 - 2026）
- 膝关节骨关节炎
- 髋关节骨关节炎
- 手骨关节炎
地区前景（收入，百万，2015 - 2026）的粘液塑料
- 北美
- 我们。
- Canada
- 欧洲
- Germany
- 英国
- 法国
- Italy
- 亚太地区
- 中国
- India
- 日本
- 澳大利亚
- 拉美
- Brazil
- 墨西哥
- 中东和非洲
- 阿联酋
- 沙特阿拉伯